Belegger.nl

Flatlander 27 januari 2021 04:25

3

The Gene Fusion Assay data looks good.
www.biocartis.com/en/publications/onl...

The Combination of EGFR and Gene fusion really fills out the Idylla Lung Cancer menu.
I have to watch it, I'm having another one of those BCART optimistic episodes. If they can move both gene fusion and EGFR to a fully approved IVD, they could really fill a niche for smaller lower throughput labs, hospitals. I'm basing this optimism on the following:

The price point for the Idylla console will look good good relative to the Thermo (Oncomine) or Illumina Minseq platform costs;

All of the major actionable fusions are covered.

The speed and ease of Idylla use;

No genetic counseling is required to interpret results;

The following video from a competitor's site identifies factors that should be considered for choosing a platform for NTRK fusions. They identify several factors that appear to be positives for Idylla.

www.ntrktesting.com/optimizing-ngs-fo...

Strange that BCART really downplays this information.

FL

[verwijderd] 27 januari 2021 10:13

0

keep the faith and be patient... i think this will work in the future for biocartis ! ik zit er al lang in en wordt met de dag optimistischer , nu de koers nog ...

Bob de Bouwer 59 27 januari 2021 19:29

0

en zo is het maar net.
Hou VOL !

Flatlander 27 januari 2021 22:30

0

Idylla Thailand

biogenic.co.th/home.html

FL

Flatlander 27 januari 2021 23:12

0

I read a very interesting report concerning Precision Medicine and MDx testing. I'd highly encourage anyone investing in BCART to read the following:

"Pharma Precision Readiness Report 2020, NCLS an axis of Change"
Diaceutics November 2020
docsend.com/view/cztpstzsehqtfit3

It was free but I doubt that the link will work since they want you to sign in with Diaceutics.

There were several interesting figures and key take aways:

On average 3 to 6 years are required between biomarker test introduction and widescale use/reimbursement.

Laboratory developed testing LDT constitutes between 40 to 70% of the biomarker NSCLC testing currently being done. These tests currently undergo little in the way of FDA approvals in the U.S. Correspondingly, as many as 60% of the insurance reimbursement requests may be denied since the LDT is largely unapproved;

Figure 7 is particularly interesting Currently (in 2020) there are 7 targeted NSCLC drugs that act on a specific molecular pathway. They collectively represented $5.3Billion in sales. There are 2050 molecular pathology labs offering IHC MDx testing. Collectively they have NSCLC revenues of $125 million. Hence, the reports major finding is that there is a major imbalance in the reimbursement rate for the MDx labs vs the the Pharma companies, considering the value they bring to the process.

Diaceutics has a decidedly lab based focus but it becomes very apparent that the market is extremely fragmented and wide open for disintermediation. Speed, automation, available on demand, and cost reduction are huge factors in favor of Idylla. However, the market is presently commoditized with hundreds of MDx providers keeping a lid on the biomarker testing/reimbursement costs. On the bright side, if Idylla can secure registrations and CPT reimbursement codes their costs, speed, ease of use are factors that favor the Idylla MDx testing platform, so they could be in a good position to disintermediate the industry. On the downside, before they secure the IVD registration approvals they are in a very crowded market. I still believe that there is a place for both PCR and NGS winners, but this really needs to be the inflection year.

FL

Flatlander 28 januari 2021 03:43

0

The interesting thing about the Thailand marketing is that it appears that most assays are registered and approved for diagnostic use. I'm basing this on the observation that ct EGFR is listed as RUO and the majority of the others are not listed as RUO. Not a big country or market but they are likely to carry the EGFR mutation at higher levels like other Asian populations. Also, the price point for Idylla should be attractive in Thailand relative to NGS.

FL

ElTorro 28 januari 2021 11:52

0

Great to see how shorters are being squeezed out in US markets.

Flatlander 28 januari 2021 14:05

0

Yep, but it remains unseen how the Robin Hooder's will exit these positions. It is likely that some new investors that are just chasing momentum get crushed. But I do enjoy watching some of the Hedge funds have to squirm looking for a bailout.

FL

[verwijderd] 28 januari 2021 14:25

0

I love it, the reddit forum is going mad over this and even big boys are jumping on the mad-train. Late last night, Melvin had to be financied for 3billion just to keep it's head above water.

DeZwarteRidder 28 januari 2021 14:28

0

quote:
Flatlander schreef op 28 januari 2021 14:05:
Yep, but it remains unseen how the Robin Hooder's will exit these positions. It is likely that some new investors that are just chasing momentum get crushed. But I do enjoy watching some of the Hedge funds have to squirm looking for a bailout.
FL

De late instappers gaan vele miljarden verlies lijden.

Flatlander 28 januari 2021 16:55

0

One of the few times I agree with DZR.

This is being portrayed as the little guy millennial on reddit rising up against the system. I think we'll eventually find that there are more orchestrated/sophisticated origins to these short squeezes.

FL

GoedeDag 28 januari 2021 17:27

0

It's exactly what they accuse hedge funds of doing, screwing over the little guy.

With of course the instigators and lucky early adopters who got out & loaded. Rest massive loss

ElTorro 28 januari 2021 22:16

1

On the market someone always pays the price, that's the game we're into, and the risk we are willing to take when buying stocks. Stocks like tesla are also very much overpriced, I don't see anyone complaining there..

Let's not forget the billions and billions of money that companies like citadel already made with their short positions, also in this company by the way.
Also reason why BCART had to pay off short position not long ago, what was that all about.

Look @ what's going on today with brooker Robinhood not allowing buying of these stocks anymore, only selling.. pure manipulation of the market.. I see some kind of panic in Wallstreet, and I do not particularly think that's a bad thing.

Flatlander 29 januari 2021 01:12

2

Cepheid Blow out 4th Qtr
The Cepheid COVID test has noted advantages over Idylla:
It runs in half the time (45 min);
It can be configured to analyze up to 80 cartridges at a time;
Combination cartridges that include flu are available; and
More than 10X the number of Cepheid consoles deployed.

None the less, it does show the promise of the business model. The point about placing consoles where they can drive future cartridge consumption is especially relevant to BCART.
FL
www.genomeweb.com/business-news/danah...

"Meanwhile, Cepheid, part of the Diagnostics segment, saw more than 100 percent core growth and passed $2 billion in annual revenue, one year after hitting the $1 billion mark, Blair said, and Radiometer and Leica Biosystems, also housed in Diagnostics, both had high single-digit revenue growth in the quarter.

During the quarter, Cepheid shipped approximately 9 million test cartridges, and Blair said the firm expects to ship 9 million during each quarter this year. Approximately 60 percent of the respiratory tests shipped were for SARS-CoV-2 only, while 40 percent were the 4-in-1 test for SARS-CoV-2, influenza A/B, and respiratory syncytial virus, he added. In Asia, there was a preference for the SARS-CoV-2-only test because the flu isn't as prevalent there, but in Europe there has been increasing adoption of the 4-in-1 test, although it's been staggered country by country, Blair said.

Cepheid also placed "a record number" of new GeneXpert systems, increasing its installed base 35 percent in 2020 to more than 30,000 instruments globally. Blair said the company has been thoughtful in placing those instruments, so they will "find great utilization" in the long term once COVID-19 testing demand has decreased."

ElTorro 29 januari 2021 13:16

0

Seems Robinhood is also working together with Citadel, that bailed out Melvin Capital. How ironic is that!

www.tijd.be/ondernemen/banken/robinho...

JotieP 29 januari 2021 14:50

0

Hi Flatlander,

That means Cepheid can deploy 160 cartridges per 90 minutes, while biocartis could do only 6.
Howmuch does it cost for a cartridge op Cepheid?
If they are more or less in the same price range, then i start to understand why biocartis doesn't find any traction... ?
Can you help me see why hospitals should choose biocartis above cepheid?

kind regards
JotieP

Flatlander 30 januari 2021 00:59

0

JotieP

I see $19.80 per cartridge.

www.finddx.org/pricing/genexpert/

The Genexpert Cepheid system has a decade head start on BCART. They were the first mover in the POC infectious disease POC market. I think the similarity of the Cepheid system is one of the reasons BCART indicated their focus was oncology. The move into infectious disease was initiated to salvage what would otherwise be a lost year. Oncology POC MDx still has no dominant provider, so I think BCARTs decision was correct at the time. A number of MDx companies changed focus to make up for the reduced volumes. EXAS did the same and has salvaged their year, HTGM didn't make the move and has struggled.

FL

Gijpie 30 januari 2021 13:33

0

Flat I read somewhere that our beloved ( in case of Biocartis) Thermo Fischer sells 40 % of the Corona tests in the world. That’s pretty impressive baering in mind the number of testing worldwide . So i do find it a bit strange that they were dashing Biocartis cause it does operate in a niche market ( oncologie) and are realy no competition for big players like Cepheid and Exas on their domain . I like to think they would of want to have a slice of the worldwide oncologie testing also and that’s a big market too . So this can only have a few reasons either they see no future in the technologie , or it’s too expensive , or ....... . Lastly i want to ask if you know Genprex inc they developped imunotherapie for the oncologie last stage market . Their going into phase 3 , all that i read from them is pretty impressive so i took the gamble and bought a slice ( 4,32 )

Flatlander 30 januari 2021 17:58

0

Gijpie

Fisher is very focused on the POC market. Last years attempted acquisition of Quidel and this years acquisition of Mesa provide proof of their intent to bulk up as a POC. provider.
Fisher offers MDx products that compete head to head with Idylla. The new Lung cancer Gene Fusion Assay's is direct competition to Fisher's Ocomine fusion test. That said the Fisher exchange provides the largest MDx platform and is used by hundreds of companies in the field. I think they would distribute Idylla products without bias in an agnostic manner if the customer knew exactly what they wanted. If they did not do this I'm sure they would have been sued by now. I just don't think that Fisher would go out of their way to recommend Idylla over their own products. BCART really needed a dedicated sales force that could market, educate and trouble shoot on behalf of clients. I think it was the right decision, but it will take years to play out.

EXAS is putting most of their eggs in the liquid biopsy basket. It seems like they are committed to expanding their laboratory testing program rather than moving into the POC market. If the technology is able to detect circulating tumors at low concentration and then be able to identify the organ where the cancer originated from, it will be a practice changing home run technology. I think BCART is more of a singles and doubles type of technology. BCART needs for the registration to allow diagnostic use so it can be used as a CDx. The technology looks like it would be a good fit in emerging markets with less access to NGS and also in some smaller hospitals and medical practices. However, the fact is that most Dr's don't have access to MDx data when initially prescribing treatment. the field is evolving albeit, slowly. As I have said in the past, the growth trajectory of Idylla could play out like Cepheids Gene Expert over a decade or more. We are very early in the roll-out. I would look for signals as we come out of the pandemic as to where the greatest traction exists.

meticulousblog.org/top-10-companies-i...

www.prnewswire.com/news-releases/ther...

I really do not know much about Genprex, so I'll need to do some reading.

FL

Flatlander 1 februari 2021 14:58

3

Septicyte Rapid Presentation

Data Demonstrate the Performance of SeptiCyte® RAPID is Unaltered by Patient Malignancy or Treatment with Anti-neoplastics or Immunosuppressants

FL

www.prnewswire.com/news-releases/immu...

Vertraagd	22 sep 2023
Koers	0,290
Verschil	0,000 (0,00%)
Hoog	0,000
Laag	0,000
Volume	0
Volume gemiddeld	0
Volume gisteren	112.228

Biocartis « Terug naar discussie overzicht

Biocartis forum geopend

Meedoen aan de discussie?

Direct naar Forum

Detail

Biocartis nieuws